(CRON) Cronos - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.024m USD | Total Return: 38.5% in 12m
Avg Turnover: 3.20M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 0
Warnings
Choppy
Tailwinds
No distinct edge detected
Cronos Group Inc. (CRON) is a Canadian cannabinoid firm specializing in the cultivation, marketing, and distribution of cannabis derivatives across North America, Israel, and international markets. Its portfolio includes dried flower, oils, and edibles sold under brands such as Spinach and Peace Naturals. The company operates within the global cannabis sector, which is characterized by high regulatory fragmentation and a shift toward value-added consumer packaged goods.
The business model relies on a multi-brand strategy to target distinct consumer segments, ranging from adult-use recreational products to wellness-focused tinctures. Strategically, the industry is increasingly focused on large-scale production efficiencies and international export opportunities as legal frameworks evolve. For a deeper look at the fundamental metrics of this stock, ValueRay provides detailed quantitative analysis.
- Strong cash position and strategic backing from Altria provide significant downside protection
- Market share growth for Spinach brand in Canadian adult-use category drives revenue
- International expansion into Israel and Germany offsets domestic regulatory and pricing pressures
- Operating loss reduction through manufacturing outsourcing and cost-cutting measures improves margins
- U.S. federal cannabis rescheduling remains primary catalyst for long-term market entry strategy
| Net Income: -2.01m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 2.91 > 1.0 |
| NWC/Revenue: 431.9% < 20% (prev 710.8%; Δ -278.9% < -1%) |
| CFO/TA 0.03 > 3% & CFO 38.9m > Net Income -2.01m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 21.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (385.3m) vs 12m ago -0.43% < -2% |
| Gross Margin: 32.81% > 18% (prev 0.28%; Δ 3.25k% > 0.5%) |
| Asset Turnover: 17.66% > 50% (prev 10.80%; Δ 6.86% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.76 (Total Current Assets 930.9m - Total Current Liabilities 42.6m) / Total Assets 1.18b |
| B: 0.39 (Retained Earnings 462.1m / Total Assets 1.18b) |
| C: -0.01 (EBIT TTM -15.0m / Avg Total Assets 1.16b) |
| D: 22.23 (Book Value of Equity 1.08b / Total Liabilities 48.5m) |
| Altman-Z'' = 29.49 = AAA |
| DSRI: 1.00 (Receivables 52.5m/31.8m, Revenue 205.7m/124.6m) |
| GMI: 0.84 (GM 32.81% / 27.65%) |
| AQI: 1.05 (AQ_t 0.09 / AQ_t-1 0.08) |
| SGI: 1.65 (Revenue 205.7m / 124.6m) |
| TATA: -0.03 (NI -2.01m - CFO 38.9m) / TA 1.18b) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 2.84 with a total of 1,303,229 shares traded.
Over the past week, the price has changed by +4.03%,
over one month by +10.08%,
over three months by +6.37% and
over the past year by +38.54%.
Cronos has received a consensus analysts rating of 3.40. Therefore, it is recommended to hold CRON.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 2.5 | -13% |
P/E Forward = 26.1097
P/S = 6.9845
P/B = 0.9501
Revenue TTM = 205.7m USD
EBIT TTM = -15.0m USD
EBITDA TTM = -12.1m USD
Long Term Debt = 1.15m USD (estimated: total debt 1.32m - short term 170k)
Short Term Debt = 170k USD (from shortTermDebt, last quarter)
Debt = 1.32m USD (from shortLongTermDebtTotal, last quarter) (leases 1.31m already included)
Net Debt = -823.2m USD (calculated: Debt 1.32m - CCE 824.6m)
Enterprise Value = 200.6m USD (1.02b + Debt 1.32m - CCE 824.6m)
Interest Coverage Ratio = unknown (Ebit TTM -15.0m / Interest Expense TTM 0.0)
EV/FCF = 7.58x (Enterprise Value 200.6m / FCF TTM 26.5m)
FCF Yield = 13.20% (FCF TTM 26.5m / Enterprise Value 200.6m)
FCF Margin = 12.87% (FCF TTM 26.5m / Revenue TTM 205.7m)
Net Margin = -0.98% (Net Income TTM -2.01m / Revenue TTM 205.7m)
Gross Margin = 32.81% ((Revenue TTM 205.7m - Cost of Revenue TTM 138.2m) / Revenue TTM)
Gross Margin QoQ = 41.42% (prev 17.73%)
Tobins Q-Ratio = 0.17 (Enterprise Value 200.6m / Total Assets 1.18b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.32m)
Taxrate = 13.39% (2.39m / 17.9m)
NOPAT = -13.0m (EBIT -15.0m * (1 - 13.39%)) [loss with tax shield]
Current Ratio = 21.87 (Total Current Assets 930.9m / Total Current Liabilities 42.6m)
Debt / Equity = 0.00 (Debt 1.32m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 68.13 (negative EBITDA) (Net Debt -823.2m / EBITDA -12.1m)
Debt / FCF = -31.10 (Net Debt -823.2m / FCF TTM 26.5m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.17% (Net Income -2.01m / Total Assets 1.18b)
RoE = -0.19% (Net Income TTM -2.01m / Total Stockholder Equity 1.08b)
RoCE = -1.39% (EBIT -15.0m / Capital Employed (Equity 1.08b + L.T.Debt 1.15m))
RoIC = -1.15% (negative operating profit) (NOPAT -13.0m / Invested Capital 1.13b)
WACC = 9.39% (E(1.02b)/V(1.03b) * Re(9.40%) + D(1.32m)/V(1.03b) * Rd(0.0%) * (1-Tc(0.13)))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.71 | Cagr: 0.12%
[DCF] Terminal Value 71.88% ; FCFF base≈26.5m ; Y1≈26.6m ; Y5≈28.2m
[DCF] Fair Price = 3.20 (EV 372.2m - Net Debt -823.2m = Equity 1.20b / Shares 373.7m; r=9.39% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.43 | # QB: 0
Revenue Correlation: 94.18 | Revenue CAGR: 35.41% | SUE: -0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.01 | Chg30d=N/A | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.01 | Chg30d=N/A | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.12 | Chg30d=+34.61% | Revisions=+33% | GrowthEPS=+537.7% | GrowthRev=+31.4%
EPS next Year (2027-12-31): EPS=0.15 | Chg30d=+25.32% | Revisions=+20% | GrowthEPS=+21.9% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +33%